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Ischemia reperfusion (IR) injury is a major issue in cardiac transplantation and inﬂammatory processes
play a major role in myocardial IR injury. MicroRNA 26a (Mir-26a) plays important roles in cellular
differentiation, cell growth, cell apoptosis and metastasis. Mir-26a has been demonstrated to modulate
regulatory T cells expansion and attenuates renal IR injury. However, the role of Mir-26a in the cardiac IR
injury has never been investigated. In our study, hearts of C57BL/6 mice were ﬂushed and stored in cold
Bretschneider solution for 8 hours and then transplanted into syngeneic recipients. The results
demonstrate a crucial role for Mir-26a in inhibiting high mobility group box-1 (HMGB1) expression and
attenuating cardiac IR injury. Mir-26a overexpression results in attenuated cardiac IR injury and inhibited
HMGB1 expression. Mir-26a also inhibits inﬂammatory cells inﬁltration and cytokines expression.
Furthermore, the attenuated cardiac IR injury induced by Mir-26a was abrogated by additional admin-
istration of recombinant HMGB1 (rHMGB1). In conclusion, Mir-26a plays a protective role in car-
diomyocyte IR injury and this is associated with inhibited HMGB1 expression.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ischemic heart disease remains the major cause of morbidity
and mortality. Myocardial inﬂammatory responses initiated by
ischemia and reperfusion (IR) worsen myocardial injury andmatrix
protein remodeling, which cause adverse cardiac remodeling and
exaggerated heart failure following IR injury (1).
MicroRNAs (MirRNAs) are small noncoding RNAs that act as
transcriptional and posttranscriptional regulators and are specif-
ically expressed by certain organs or cell types. Dysregulation of
MiRNAs expression and function is associated with a variety of
human diseases, including cancer and many inﬂammatory diseases
(2), and alterations in miRNA function can therefore potentially
serve as useful diagnostic markers for these pathologies (3).
MicroRNA 26a (Mir-26a) has been reported to play important roles
in cellular differentiation, cell growth, cell apoptosis andmetastasiseneral Internal, No. 27 East
, PR China.
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d/4.0/).(4e7). Recent study indicated that Mir-26a modulated Th17/Treg
balance and attenuated multiple sclerosis in a mouse experimental
autoimmune encephalomyelitis (EAE) model (8). Moreover, mir-
26a has been demonstrated to modulate regulatory T cells expan-
sion and attenuates renal IR injury (9). However, the role of Mir-26a
in the cardiac IR injury has never been investigated.
In our current study, we demonstrate a crucial role for Mir-26a
in inhibiting high mobility group box-1 (HMGB1) expression and
attenuating cardiac IR injury. Mir-26a overexpression results in
attenuated cardiac IR injury and inhibited HMGB1 expression. Mir-
26a also inhibits inﬂammatory cells inﬁltration and cytokines
expression. Furthermore, the attenuated cardiac IR injury induced
by LV-26a was abrogated by additional administration of recom-
binant HMGB1 (rHMGB1).2. Materials and methods
2.1. Mouse cardiac IRI model
Animal facilities and protocols were approved by the Laboratory
Animal Care and Use Committee of Linyi People's Hospital. C57BL/6
wild-type male mice (6e8 wk of age, weighing 20e25 g) werenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
L. Yao et al. / Journal of Pharmacological Sciences 131 (2016) 6e12 7purchased from Shandong University. Syngeneic heterotopic heart
transplantation was performed by a modiﬁed non suture cuff
technique previously described by Heron et al (10). Brieﬂy, the
donor heart was heterotopically transplanted to the neck vessels of
the recipient: the aortic root was anastomosed to the right common
carotid artery and the pulmonary artery to the right jugular vein of
the recipient. Hearts were stored in cold Bretschneider solution for
8 hours before transplantation with consecutive in vivo reperfusion
for 24 h (11). In some recipients, recombinant HMGB1 (100 mg/kg)
was injected intravenously prior to reperfusion (12). In some mice,
5 mg of recombinant mouse IL-17 [rmIL-17] (R&D Systems) was
intraperitoneal injected 5 minutes prior to reperfusion. For inhi-
bition of HMGB1, mice were treated with glycyrrhizin (TCI,
Shanghai, China) at 5 mg/mouse 5 minutes prior to reperfusion
(13).
2.2. Serum analysis of cardiac troponin T
Analysis of cardiac serum TnT levels were performed as follows:
1 mL of heparinized blood was centrifuged to obtain plasma and
stored at 30 C until assayed. TnT was measured using the cardiac
reader system according to the manufactures' instruction.
2.3. Histopathology and immunohistochemistry
Cardiac graft tissues were stained with hematoxylin-eosin (HE).
For immunohistochemical staining, 5 mm sections of cryostat frozen
tissue were applied to poly-L-lysine microscope slides (Sigma-
eAldrich, Saint Louis, MO), and ﬁxed with cold acetone. To quantify
leukocyte inﬁltration, sections were stained with rat anti-mouse
Ly6G, F4/80 and HMGB1 antibody (Abcam, Cambridge, MA) fol-
lowed by goat anti-rat biotin conjugate. The number of macro-
phages and neutrophils were assessed in 10 ﬁelds per slide at a
magniﬁcation of  400, and the results were expressed as cells per
high-power ﬁeld.
2.4. Myeloperoxidase assay
On 24 h post transplantation, tissue samples from cardiac iso-
grafts were assessed for MPO activity (14). Samples were homog-
enized in hexadecyltrimethyl ammonium bromide
(SigmaeAldrich, St. Louis, MO) and dissolved in potassium phos-
phate. After centrifugation, supernatants were collected and mixed
with o-dianisidine dihydrochloride (SigmaeAldrich, St. Louis, MO)
and H2O2 in phosphate buffer. The activity of MPO was measured
spectrophotometrically at 470 nm using microplate Reader
(ELx800, Bio-Tek Instruments, USA) and expressed as units per
100 mg tissue. Myeloperoxidase standards (SigmaeAldrich, St.
Louis, MO) were measured concurrently with the tissue samples.
2.5. Real-time PCR
Cardiac tissue samples were initially snap-frozen in liquid ni-
trogen. Total RNA was extracted using Trizol reagent and the miR-
Neasy Mini kit (Qiagen, Valencia, CA) following manufacturer's
instructions. cDNA was prepared as recommended (Progema) and
used as the template for quantitative PCR. Levels of Mir-26a and
mRNA for TNF-a, IFN-g, IL-1b, IL-17, TLR2, TLR4, RAGE and HPRT
were analyzed by real-time PCR, performed according to the
manufacture's instruction (Takara BioInc., Otsu, Shiga, Japan). The
forward RT-PCR primer for Mir-26a was 50-AAGGAGAACCCGTA-
GATCCG-30, and the reverse one was 50-GTGCAGGGTCCGAGG-
TATTC-30. Transcript levels were normalized to the expression of
HPRT. Analyses were performed with the Sequence Detection
Software 1.9 (SDS).2.6. Myocardial apoptosis
Terminal deoxynucleotidyl-transferase mediated dUTP nick-end
labeling (TUNEL) staining was performed as previously described
(14). Hearts were ﬁxed in 4% paraformaldehyde, embedded in
parafﬁn, cut into 5-mm thickness sections and treated as instructed
in the In Situ Cell Death Detection kit (Roche Diagnostics GmbH,
Mannheim, Germany). Total nuclei were stained with DAPI. Cardiac
caspase-3 activity was measured as previously described (15) using
a caspase colorimetric assay kit following the manufacturer's in-
structions (Chemicon, Temecula, CA). The absorbance of the p-
nitroaniline cleaved by caspase was measured at 405 nm using a
microplate reader (ELx800, Bio-Tek Instruments, USA). Results
were standardized to the sham group for comparison of the fold
change in caspase-3 activity.
2.7. Western blotting
The protein levels were determined byWestern blotting. Protein
extracted from cells or tissue was separated on 10% SDS-
polyacrylamide electrophoresis gels and transferred to nitrocellu-
lose membranes (Pierce, Rockford, IL). After being blocked with 5%
non-fat milk in TBS for 3 hours, the membranes were incubated
with indicated primary antibodies (0.2 mg/ml) at 4 C overnight,
followed by incubation with HRP-conjugated secondary antibody
(1:5000) for 3 hours. b-actin was used as a loading control for
comparison between samples.
2.8. Statistical analysis
Data are expressed as means ± SEM.; the t-test and one-way
analysis of variance were used for comparisons of means be-
tween experimental groups. KaplaneMeier curve was used to es-
timate graft survival time. Differences were considered to be
signiﬁcant at P < 0.05. We analyzed the data using GraphPad Prism
software (GraphPad Software, La Jolla, CA).
3. Results
3.1. Mir-26a attenuates cardiac IR injury
We ﬁrst explored the expression of Mir-26a in cardiac with IR
injury by quantitative reverse transcriptase PCR. Cardiac tissues at
24 h after IR injury showed signiﬁcantly lower expression of Mir-
26a (Fig. 1A). Next, we investigated the potential effects of Mir-
26a on cardiac IR injury through the construction of lentiviral
vectors. Vectors encoding pre-Mir-26a (LV-26a) and an empty
lentiviral vector (LV-Con) delivered approximately 2  107 trans-
forming units of recombinant lentivirus to mice by injection
through the tail vein. The efﬁcacy of lentivirus infection was
assessed 7 days later by quantitative real-time PCR analysis of Mir-
26a expression in the spleen of LV-26a-infected mice and LV-Con-
infected mice (P < 0.05, Fig. 1B). Lentivirus-infected mice were
established cardiac IR injury on day 7 after virus injection. Relative
to LV-Con-infected mice, LV-26a-infected mice exhibited
decreased TnI levels on 24 h after cardiac IR injury (Fig. 1C).
Furthermore, LV-26a treatment protected cardiac tissue injury as
compared with the LV-Con group on 24 h after cardiac IR injury
(Fig. 1D).
Apoptosis contributes signiﬁcantly to myocardial IR injury. We
carried out terminal deoxynucleotidyl-transferase mediated dUTP
nick-end labeling (TUNEL) of cardiac isografts from different
experiment groups at 24 h post-transplantation. We found that LV-
26a administration signiﬁcantly decreased the number of TUNEL-
positive cardiomyocytes in comparison with control group
Fig. 1. Mir-26a attenuates cardiac IR injury. A, Mir-26a mRNA expression was analyzed by RT-PCR method; B, Quantitative PCR analysis of Mir-26a mRNA expression in the spleen of
mice infected with LV-Mir-26a or LV-Con (day 7 after lentivirus administration); C, Indicating the serum levels of TnI on 24 h after cardiac IR injury; D, Indicating the HE staining of
cardiac allograft on 24 h after cardiac IR injury; E, Percentages of TUNEL-positive nuclei over total number of nuclei; F, Caspase 3 activity in cardiac isograft was assessed 24 h post
transplantation, and the values were normalized to sham. P < 0.05. n ¼ 6.
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assay from cardiac isografts was concomitantly down regulated by
LV-26a treatment (Fig. 1F).3.2. Mir-26a inhibits inﬂammatory cells inﬁltration and cytokines
expression
Neutrophil inﬁltration is a hallmark of inﬂammatory injury after
myocardial IR injury (16). Therefore, we investigated the function of
LV-26a on neutrophil recruitment. As determined by myeloperox-
idase activity and immunohistological analysis of Ly6Gþ neutro-
phils, myocardial IR injury induced a surge in neutrophil
recruitment to myocardium and LV-26a treatment decreased
neutrophil recruitment (Fig. 2AeC). Macrophage migration is an
important factor in IR injury in heart (17). We found that myocar-
dial IR injury was characterized by a drastic increase in the inﬁl-
tration of F4/80þ monocytes/macrophages after cardiac IR injury.This increase in cardiac monocytes/macrophages was signiﬁcantly
reduced in LV-26a-treated mice (Fig. 2AeB).
Wenextmeasured cardiacmRNAwith real-time quantitative PCR.
Results indicated that the LV-26a treatment signiﬁcantly down-
regulated the expressions of proinﬂammatory cytokines (IFN-g, IL-1b
and IL-17), TLR2/4andRAGEon24hwhencompared to that incontrol
group. On 24 h post-reperfusion, the cytokines mRNA expressions of
TNF-awas not signiﬁcantly different between the two groups (Fig. 3).3.3. Mir-26a inhibits HMGB1 expression in cardiac allograft
HMGB1, a highly conserved nuclear protein, served as an early
mediator of inﬂammation and cell injuryand plays a key role inmany
pathogenic states includingmyocardial IR (18). Sowe investigated the
HMGB1 expression in cardiac allograft. Results from immunohisto-
logical study showed that LV-26a treatment signiﬁcantly reduced
HMGB1expressionas comparedwith LV-Congroup (Fig. 4A). The PCR
Fig. 2. Mir-26a inhibits inﬂammatory cells inﬁltration. A. Immunohistological analysis of Ly6Gþ neutrophils and F4/80þmonocytes/macrophages; B, Indicating the number of Ly6Gþ
neutrophils and F4/80þ monocytes/macrophages in cardiac allograft on 24 h after cardiac IR injury; C, Cardiac myeloperoxidase activity in tissue samples. P < 0.05. n ¼ 6.
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26a on HMGB1 expression in cardiac allograft (Fig. 4BeC).
3.4. Mir-26a attenuates cardiac IR injury in part though inhibited
HMGB1 expression
In order to further investigate the role of HMGB1 in attenuated
cardiac IR injury induced byMir-26a treatment, we ﬁrst studied the
effect of HMGB1 antagonist in cardiac IR injury. Results indicated
that inhibition of HMGB1 with Glycyrrhizin signiﬁcantly reduced
the serum TnI level and cardiac MPO activity (Fig. 5AeB). Next, we
administrated the cardiac allograft recipients with recombinant
HMGB1 (rHMGB1) in addition to LV-26a or LV-Con. We found that
both the reduced serum TnI level and cardiac MPO activity induced
by LV-26a was reversed by additional administration of rHMGB1
(Fig. 5CeD).
4. Discussion
Our current study provides strong evidence that Mir-26a is
involved directly in cardiac innate immune response against IRinjury by inhibiting HMGB1 expression. Mir-26a overexpression
results in attenuated cardiac IR injury and inhibited HMGB1
expression. Mir-26a also inhibits inﬂammatory cells inﬁltration and
cytokines expression. Furthermore, the attenuated cardiac IR injury
induced by LV-26a was abrogated by additional administration of
recombinant HMGB1 (rHMGB1).
Ischemia reperfusion triggers a vigorous inﬂammatory
response, augmented by the generation and release of various cy-
tokines that ultimately exacerbates tissue injury, although the
precise mechanism of the ischemia reperfusion injury has not been
fully revealed (19). Invading inﬂammatory cells play an important
role in cardiac IR injury, capable of releasing degrading enzymes
and producing large amount of ROS (20), the inﬂammatory
response is further enhanced by the myocardium through the
release of chemoattractant factors and many other mediators in
which necrotic cell death is known to play an important role
(21,22). In our current study, treatment of LV-26a signiﬁcantly
inhibited the inﬁltration of Ly6Gþ neutrophils and F4/80þ macro-
phages. The inﬂammatory cytokines including IFN-g, IL-1b and IL-
17 were also markedly reduced in LV-26a-treated recipient as
compared with LV-Con-treated recipients. All of these indicated
Fig. 3. Mir-26a inhibits inﬂammatory cytokines expression. The mRNA expression of TNF-a, IFN-g, IL-1b, IL-17, TLR2, TLR4 and RAGE were measured by RT-PCR. *P < 0.05. N ¼ 6.
Fig. 4. Mir-26a inhibits HMGB1 expression in cardiac allograft. A, Immunohistological analysis of HMGB1 expression in cardiac allograft on 24 h after cardiac IR injury; B, HMGB1
mRNA level in cardiac allograft on 24 h after cardiac IR injury was analyzed by PCR method; C, HMGB1 protein level in cardiac allograft on 24 h after cardiac IR injury was analyzed
by Western blotting. *P < 0.05. N ¼ 6.
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Fig. 5. Mir-26a attenuates cardiac IR injury in part though inhibited HMGB1 expression. A, Indicating the serum levels of TnI in control and Glycyrrhizin group; B, Indicating the
cardiac MPO activity in control and Glycyrrhizin group; C, Indicating the serum levels of TnI in LV-Con, LV-26a, LV-26aþrHMGB1 and LV-ConþrHMGB1 groups; D, Indicating the
cardiac MPO activity in LV-Con, LV-26a, LV-26aþrHMGB1 and LV-ConþrHMGB1 groups. *P < 0.05. N ¼ 6.
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uated cardiac IR injury induced by Mir-26a.
Activation of the innate immunity is an essential component of
the acute inﬂammatory response in the setting of IR injury. The key
role of neutrophils, monocytes, macrophages and dendritic cells
has been demonstrated in innate immunity. However, recent
experimental lines of evidence have suggested that ischemic car-
diomyocytes can also contribute to the innate immune response
besides being a target organ. Toll-Like Receptors (TLR), originally
identiﬁed 20 years ago for its role in the embryonic development of
the fruit ﬂy Drosophila melanogaster, have been later recognized as
a key elements of the immune system (23,24). The discovery of the
notably contribution of TLR2 and TLR4 in the development of
atherosclerotic lesions and vascular remodeling frosted the interest
in deciphering their potential role in the setting of myocardial IR
(25e27). Although the mechanisms involved in TLR 2 and 4 acti-
vation in myocardial IR remain to be fully described, a variety of
endogenous molecules have been identiﬁed to act as potential
endogenous damage-associated molecular patterns (DAMPs).
Myocardial cell necrosis triggered during ischemia results in the
release of necrotic products and cellular constituents such as heat
shock proteins (HSP) and nuclear DNA-binding protein high
mobility group box (Hmgb-1) capable of activating the TLR2 and
TLR4 signaling (28). In our current study, the expression of TLR2
and TLR4 were signiﬁcantly inhibited by LV-26a treatment. The
HMGB1 expression was also markedly suppressed in LV-26a-
treated mice. This was consistent with previous reports indicating
the interaction of TLR2/4 with HMGB1 in cardiac IR injury.It has previously been shown that HMGB1 is a potent innate
‘danger signal’. HMGB1 has been demonstrated to initiate and
amplify the inﬂammatory response following IR injury (29). Recent
studies have shown that HMGB1, acting via the receptor for
advanced glycation end products (RAGE) or members of the Toll-
like family of receptors (TLRs), is an early mediator of organ dam-
age in myocardial injury (30,31). Blockage of HMGB1 with HMGB1
box A, a speciﬁc antagonist of whole HMGB1 on the RAGE receptor,
or anti-HMGB1 monoclonal antibody has been proved to exert
beneﬁt against IR injury (32,33). In our current study, results
indicated that inhibition of HMGB1 with glycyrrhizin signiﬁcantly
reduced the serum TnI level and cardiac MPO activity. Furthermore,
both the reduced serum TnI level and cardiac MPO activity induced
by LV-26a was reversed by additional administration of rHMGB1.
All of these demonstrated that Mir-26a protect cardiac against IR
injury at least in part through inhibition of HMGB1 expression.
In summary, our study provides evidence that Mir-26a played a
protective role in cardiomyocyte IR injury and this was associated
with inhibited HMGB1 expression. Although further investigations
are needed to fully clarify the precise molecular and cellular
mechanism involved in the immunoregulation, Mir-26a may be
exploited as a novel therapeutic agent to attenuate IR injury in
cardiac transplantation.Conﬂicts of interest
None declared.
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